Heterotopic Ossification

SAN DIEGO — Results showed surgical excision paired with optimized rehabilitation for the treatment of complete elbow ankylosis due to elbow heterotopic ossification may lead to improved long-term outcomes.

The FDA approved palovarotene capsules as the first treatment for people with the rare bone disease fibrodysplasia ossificans progressiva, according to an industry press release.

According to results published in the Journal of Bone and Joint Surgery, tranexamic acid may be indicated for the prevention of heterotopic ossification following surgery for elbow trauma.

Palovarotene reduced new heterotopic ossification volume in children and adults with fibrodysplasia ossificans progressiva, according to data from a phase 3 trial.